

Review

Not peer-reviewed version

---

# Surgical Treatment and Postoperative Surveillance for Familial Adenomatous Polyposis

---

[Masatsune Shibutani](#)<sup>\*</sup>, Hiroaki Kasashima, Tatsunari Fukuoka, Kiyoshi Maeda

Posted Date: 9 January 2025

doi: 10.20944/preprints202501.0762.v1

Keywords: familial adenomatous polyposis; surgical treatment; postoperative surveillance



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

# Surgical Treatment and Postoperative Surveillance for Familial Adenomatous Polyposis

Masatsune Shibutani \*, Hiroaki Kasashima, Tatsunari Fukuoka and Kiyoshi Maeda

Department of Gastroenterological Surgery, Osaka Metropolitan University Graduate School of Medicine,  
Osaka, Japan

\* Correspondence: fbxbj429@ybb.ne.jp

**Simple Summary:** Familial adenomatous polyposis (FAP) is a hereditary disease caused by pathogenic germline variants in the adenomatous polyposis coli (APC) gene. Unless this is properly treated, then almost all patients with FAP later develop colorectal cancer. Since the risk varies by genotype, it is advisable to propose an individualized surgical procedure based on each patient's specific background. The surgical procedure should be selected based on the balance between preserving the bowel function and preventing the development of colorectal cancer. In cases undergoing total proctocolectomy, various measures are required to extend the mesentery when performing ileal pouch anal anastomosis. This review provides information on FAP, including the clinical features, appropriate timing of surgical treatment, selection of the surgical procedure (extent of resection), the surgical approach, oncologically appropriate and safe reconstruction methods, and disadvantages associated with surgery.

**Abstract** Familial adenomatous polyposis (FAP) is a genetic disease caused by an APC mutation. It develops into multiple adenomatous polyps when patients are in their early 20s and eventually transforms into colorectal cancer at 100% penetrance unless treated. Therefore, prophylactic surgery is recommended as the only effective treatment option. However, individual approaches, such as total colectomy with ileorectal anastomosis, proctocolectomy with stapled ileal pouch-anal anastomosis (IPAA), proctocolectomy with mucosectomy and handsewn IPAA, and total proctocolectomy with end ileostomy, are required based on the balance between the risk of metachronous rectal cancer, postoperative complications, and a decreased anal function. We herein summarize the current evidence regarding the surgical treatment and postoperative surveillance for FAP.

**Keywords:** familial adenomatous polyposis; surgical treatment; postoperative surveillance

## 1. Overview

Familial adenomatous polyposis (FAP) is a hereditary autosomal dominant disease caused by pathogenic germline variants of the adenomatous polyposis coli (APC) gene, a tumor suppressor gene located on the long arm of chromosome 5 (5q22.2), the main symptom of which is colorectal adenomatous polyposis [1]. As patients with FAP have an extremely high risk of developing colorectal cancer, appropriate therapeutic interventions for preventing colorectal cancer are necessary. Unless treated, approximately 50% of patients with FAP develop colorectal cancer in their 40s, and almost all patients with FAP develop colorectal cancer by 60 years old [2]. In addition, surveillance and treatment considering extracolonic lesions associated with FAP are necessary because various associated neoplastic and non-neoplastic lesions can develop in the gastrointestinal tract and other organs [1]. Neoplastic lesions, such as desmoid tumors and duodenal cancer, can also cause death in patients with FAP [3], although most deaths in patients with FAP are due to colorectal cancer [3].

2. Clinical Features

FAP is sometimes classified into three categories based on adenoma density: severe FAP, sparse FAP, and attenuated FAP (AFAP) (Table 1) [1]. Severe FAP is a phenotype with more than 1000 adenomas, in which normal colorectal mucosa cannot be endoscopically observed because of the presence of numerous adenomas. Sparse FAP is a phenotype with 100-1000 adenomas in which normal colorectal mucosa is visualized. AFAP is a phenotype with 10-100 adenomas in which germline variants are often detected. Severe and sparse FAP are collectively referred to as classical FAP. The density of adenomas is associated with the presence of germline variants in APC [1]. Classical FAP is characterized by hundreds to thousands of colorectal adenomatous polyps, with an onset at a mean age of 16 [7–36] years old. In classical FAP, 95% of patients will have polyps by 35 years old, and colorectal cancer is inevitable without intervention, such as colectomy/proctocolectomy. AFAP is associated with fewer adenomas, an older age at the diagnosis, and a lower lifetime risk of colorectal cancer than classical FAP [4,5]. According to a Japanese multicenter study, the age at which half of colorectal cancers develop was 41 years old for patients with severe FAP, 48 years old for those with sparse FAP, and 59 years old for those with AFAP [6].

**Table 1.** Classification of familial adenomatous polyposis (FAP).

	Classical FAP		attenuated FAP
	severe FAP	sparse FAP	
The number of adenomas	more than 1000	100-1000	10-100
Endoscopic features	A normal mucosa cannot be observed	A normal mucosa is visualized	
The median age at which half of the cancers develop (years)	41	48	59

3. Surveillance from the Diagnosis of FAP to Surgery

Recommendations for endoscopic surveillance for FAP are as follows: in patients with classical FAP, it is recommended to begin endoscopy at an interval of 1-2 years after reaching 10 years old [10] because colorectal cancer development is at a very low frequency before 10 years old; however, a European study found a 0.2% incidence of colorectal cancer in the early teenage years [8]. In patients with AFAP, it is recommended to begin endoscopy at an interval of 2-3 years in the late teenage years [1], as the age at which colorectal cancer develop is 10-15 years later than in patients with classical FAP, and colorectal cancer development is rare in patients under 30 years old [4,5].

4. Factors Determining the Timing of Surgery

A staging system based on the endoscopic findings, such as the number and diameter of colorectal adenomas, has been proposed by the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) [9]. This staging system, based on polyp burden, is useful for judging surgical indications. Furthermore, an increase in polyp burden indicates the need for surgical treatment [10]. In addition, the cumulative prevalence of colorectal cancer, APC gene mutation site [11,12], age at death or age at cancer onset, presence of desmoid tumors in members of the pedigree [13], social background such as education and employment [14], and fertility [15] are also important factors that determine the timing of surgical treatment. From the perspective of avoiding the development of colorectal cancer, most patients with FAP are recommended to undergo surgical treatment in their 20s, but some patients with classical FAP may be recommended to undergo surgical treatment even in their teens [16,17]. It has been reported that if surgical treatment is not performed, the risk of developing stage ≥II colorectal cancer increases dramatically after 34 years old in patients with the classical FAP genotype and after 49 years old in patients with the AFAP genotype [12].

## 5. Surgical Treatment

### 5.1. Selection of Surgical Procedure

The goal of surgery in patients with FAP is to prevent the development of colorectal cancer and maintain the quality of life. Although intensive endoscopic removal for downstaging of polyp burden in patients with mild-to-moderate FAP who request postponement of surgery or refuse to undergo surgery may prevent colorectal cancer without implementing colectomy/proctocolectomy [18,19], the most effective and reliable treatment to avoid death from colorectal cancer is prophylactic colectomy/proctocolectomy before the development of colorectal cancer.

The surgical options for FAP are (i) total proctocolectomy with end ileostomy (TPC), (ii) total proctocolectomy with ileal pouch anal anastomosis (IPAA), and (iii) total colectomy with ileorectal anastomosis (IRA). IPAA includes hand-sewn IPAA with mucosectomy of the anal transition zone (AZT), and stapled IPAA. TPC, which requires permanent ileostomy, is performed in patients with an impaired sphincter function, lower rectal cancer, or cancer requiring radiation therapy and in those who wish to avoid the functional sequelae of a pouch. IRA is a relatively simple and straightforward procedure compared to IPAA, while IPAA is a more extensive surgery than IRA, with a higher possibility of disadvantages such as pelvic abscess, fistula, reoperation, fecal incontinence, and decreased fertility [15,20]. In contrast, patients who undergo IRA may develop polyps or cancer in the remaining rectum and subsequently require additional rectal resection [21]. Owing to advances in surgical techniques, the proportion of IPAA is increasing, and IPAA is currently the most commonly selected surgical procedure for FAP. However, no randomized trials have compared the impact of IPAA and IRA on the long-term prognosis. Ardoino et al. performed a retrospective analysis of 925 cases of FAP treated surgically using data from the Italian nationwide registry, and found that the 20-year survival rate was higher in the IRA group than in the IPAA group (0.82 vs. 0.75;  $p=0.003$ ) [22]. The main prognostic factors affecting overall survival were age and the presence of cancer during surgery. Based on the above, it has been stated that IPAA is not necessarily required if there is no cancer or high-grade dysplasia and that the surgical procedure should be selected based on individual background factors. Although IRA carries a risk of rectal cancer, IRA can be offered as an option for surgical treatment of FAP, specifically when rectal adenomas of  $\geq 5$  mm can be endoscopically removed [22]. In addition, IRA plus strict follow-up with colonoscopy can also be an option for patients with  $<20$  rectal polyps because the incidence of rectal cancer development is relatively low (1.6%) in such cases [23]. Nieuwenhuis et al. also demonstrated that the cumulative risks of secondary proctectomy 20 years after primary colectomy varied by genotype (attenuated: 10%, intermediate: 39%, severe: 61%) and argued that patients with a severe genotype will benefit from primary proctocolectomy with IPAA because they have a high risk of secondary proctectomy [24]. Furthermore, according to a meta-analysis of colectomy and desmoid tumors in FAP, fewer desmoid tumors were observed after laparoscopic IRA than laparoscopic IPAA [25]. Conversely, IRA should not be selected in the following cases because of the increased risk of cancer development in the remaining rectum: rectal cancer,  $>20$  synchronous rectal adenomas, adenomas with high-grade dysplasia, polyps  $\geq 30$  mm, and cases with a severe family history of an aggressive phenotype [22]. The incidence of postoperative adenomas after hand-sewn IPAA with mucosectomy of the AZT was lower than that after stapled IPAA (22.6% vs. 51.1% at 10 years) [26]. In addition, Tatsuta et al. reported that the overall survival was significantly better in the hand-sewn IPAA with mucosectomy of AZT group than in the stapled IPAA group (96.6% vs. 63.7 at 20 years) [27], although this study was a retrospective analysis of a small number of cases. However, handsewn IPAA with mucosectomy of the AZT may result in worse functional outcomes than stapled IPAA, and there was no marked difference in the risk of postoperative cancer development between the two methods [26]. To date, there has been little evidence that mucosectomy of AZT should be performed routinely [22]. However, mucosectomy of AZT is necessary in cases where the polyp burden extends to the dentate line [22].


### 5.2. Surgical Treatment for FAP with Advanced Colorectal Cancer

Regarding surgical treatment for FAP with advanced colorectal cancer, a comprehensive judgment should be made, taking into account the TNM stage of the colorectal cancer and the location of the tumor. If radical resection of colorectal cancer is expected, total proctocolectomy, including regional lymph node dissection, may be an option [1].

### 5.3. Surgical Techniques for Mesenteric Lengthening in IPAA

Creating tension-free IPAA following proctocolectomy is an important challenge in reconstruction during the surgical treatment of FAP. In patients with obesity, a narrow pelvis, thick mesentery, and extensive adhesions, sufficient mesentery length may not be available, resulting in tension at the anastomotic site. Tension at the anastomotic site may cause ischemia, necrosis, and anastomotic leakage. Therefore, surgical lengthening techniques are required to create tension-free anastomoses.

Several surgical techniques are available for lengthening the mesentery. Folding the pouch anteriorly (with the mesentery posterior) has been reported to result in a mesentery approximately 1 cm longer than when the pouch is folded posteriorly [28]. Stepladder incision is a simple and safe technique for lengthening the mesentery (Fig.1a). It has been reported that by making serial transverse incisions of approximately 1-3 cm in width on the anterior and posterior surfaces of the mesentery, the mesentery can be lengthened by 6-8 cm [29]. If sufficient mesentery length cannot be secured even after performing stepladder incision, it may be possible to lengthen the mesentery further by skeletonizing the mesentery around the vessels (Fig.1b). In addition, although the J-type ileal pouch is popular, it has been reported that the mesentery in the S-type ileal pouch is on average 2-4 cm longer than that in the J-type ileal pouch [30]. Division and ligation of the mesenteric vessels are frequently used as lengthening techniques. It is possible to further increase the length by dividing the ileocolonic or superior mesenteric arteries. Depending on the case, an additional length of 5 cm or more can be obtained [31–33]. Ligation of the terminal ileal mesenteric artery, right colic artery, and marginal vascular arcade is another option. However, this procedure may result in decreased blood supply to the ileal pouch. If a sufficient blood supply to the terminal ileum is not ensured, there may be an increased risk of anastomotic leakage and malfunction of the ileal pouch. To maintain sufficient blood supply to the terminal ileum even after the division and ligation of the mesenteric vessels, a clamping test, in which blood flow is temporarily interrupted before the mesenteric arteries are divided, is useful. If vascular pulsations remain and the color of the intestinal tract does not change after interruption of the blood flow for 15 minutes, the mesenteric arteries can be divided safely.



**Figure 1.** Surgical techniques for lengthening the mesentery; stepladder incisions (b)skeletonization.

For tension-free anastomosis, a balance between an adequate mesenteric length and sufficient blood supply is important.



#### 5.4. Surgical Approach

In recent years, the laparoscopic approach has been adopted increasingly frequently for surgical treatment of FAP [34–37]. According to a nationwide Japanese multicenter study, the incidence of postoperative complications and the rate of preservation of the anal, urinary, and sexual functions were equivalent between laparoscopic surgery and open surgery, although the laparoscopic approach was associated with a longer operation time (TPC with IPAA: 482 min vs. 275 min, respectively,  $p < 0.001$ ) [35]. A report from the United States that examined the impact of the surgical approach to IPAA for ulcerative colitis and FAP showed that laparoscopic surgery takes longer than open surgery (266.7 min vs. 187.5 min, respectively,  $P < 0.0001$ ), but there was no significant difference between laparoscopic and open IPAA with respect to blood loss, blood transfusions, length of hospital stay, re-admission rate, and incidence of postoperative complications, and that diverting loop ileostomy closure can be performed earlier in patients who received laparoscopic IPAA than in those who received open IPAA (80.4 days vs. 104.5 days, respectively,  $p = 0.045$ ) [38]. It has also been reported that laparoscopic surgery is less likely to cause postoperative adhesions than open surgery, resulting in a lower decline in fertility [36].

#### 5.5. Disadvantages of Undergoing Surgery

Postoperative complications include anastomotic leakage, pelvic abscesses, and fistulas. The incidence of anastomotic leakage after IPAA was reported to be relatively high (6.3%) [39], although this result was obtained from a study that included patients with ulcerative colitis only, ulcerative colitis and a combination with Crohn's disease, indeterminate colitis, FAP, and colorectal cancer. Such infectious complications may necessitate reoperation and result in a permanent endileostomy. In addition, postoperative infectious complications increase the risk of pouch dysfunction, such as frequent bowel movements, fecal incontinence, and difficulty in defecation due to stenosis. Furthermore, pouchitis is also a complication that affects patients, although it is less frequent in patients with FAP than in those with ulcerative colitis. Most cases improve with antibiotics; however, some patients suffer from refractory pouchitis, which develops repeatedly in a short period and is resistant to antibiotic treatment. Pouch dysfunction and pouchitis have a significant negative impact on patients' quality of life and mental wellbeing.

Other concerns include ileus due to postoperative adhesions and, although rare, afferent limb syndrome, obstruction of passage due to flexion, and torsion at the proximal portion of the ileal pouch [40].

Other disadvantages of surgical treatment include deterioration of the body image and self-esteem. Women tend to have lower postoperative self-esteem than men [41]; however, choosing laparoscopic surgery may solve these problems.

Because surgical treatment of FAP is often performed in young patients, maintaining fertility and the sexual function is also an important issue. In men, pelvic nerve damage can cause sexual dysfunction such as difficulty in achieving erection or orgasm, and decreased sexual desire, intercourse satisfaction, and overall sexual satisfaction. In women, sexual dysfunction can also occur, such as decreased desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia. Infertility can also occur because of blockage of the fallopian tubes caused by postoperative adhesions [42].

In surgical treatment for FAP, it is important to focus on preserving the organ function so as not to reduce the patient's quality of life, as well as to prevent the development of cancer.

**Table 2.** Disadvantage of undergoing surgery.

Postoperative infectious complications	Anastomotic leakage Pelvic abscess Fistula
Pouch-related complications	Pouch dysfunction (frequent bowel movements, fecal incontinence, difficulty in defecation due to stenosis) Pouchitis
Others	Deterioration of the body image and self-esteem Decreasing fertility and the sexual function

**6. Surveillance After Surgical Treatments**

In patients who undergo IRA, cancer development in the remaining rectum is not uncommon. According to previous reports, 24%-43% of patients who undergo IRA develop cancer in the remaining rectum [43,44]. Therefore, long-term endoscopic surveillance after IRA to monitor cancer development is necessary. Annual endoscopic surveillance is typically recommended [22], but biannual endoscopic surveillance is acceptable, depending on the polyp burden [45]. Even in patients who have undergone IPAA, a small amount of rectal mucosa and AZT mucosa remains, and adenomas and cancers may develop in the ileal pouch, although the incidence is very low (the overall prevalence of pouch neoplasia is estimated to be approximately 0.01%) [45]. Therefore, long-term endoscopic surveillance is necessary for patients who have undergone IPAA. In addition, extracolonic manifestations of FAP, such as desmoid tumors and duodenal cancer, can cause death. Therefore, surveillance of extracolonic manifestations of FAP is also necessary.

**Table 3.** Surveillance after surgical treatments.

Examination	Comment
Colonoscopy	After IRA Typically annual, but biannual is acceptable depending on polyp burden After IPAA For small amount of rectal mucosa, AZT mucosa, and ileal pouch
Upper gastrointestinal endoscopy	Gastric polyps and duodenal polyps/cancer
Abdominal CT	Desmoid tumors
Thyroid ultrasound	Thyroid cancer
Brain CT	Brain tumor

IRA, ileorectal anastomosis; IPAA, ileal pouch anal anastomosis; AZT, anal transition zone; CT, computed tomography.

**7. Conclusions**

In surgical treatment for FAP, the timing and the type of procedure, especially the extent of resection and reconstruction methods, are all important factors. It is desirable to provide

individualized surgical treatment based on each patients' specific background, including the genetic type.

**Author Contributions:** Conceptualization, M.S. and K.M; supervision, H.K. and T.F.; writing—original draft, M.S.; writing—review and editing, M.S., H.K., T.F. and K.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No new data were created or analyzed in this study.

**Acknowledgments:** We thank Dr. Brian Quinn, who provided medical writing services on behalf of JMC Ltd.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

- Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, Hirasawa A, Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, Arai M, Itabashi M, Hashiguchi Y, Sugihara K; Japanese Society for Cancer of the Colon, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. *Int J Clin Oncol*. 2021 Aug;26(8):1353-1419. doi: 10.1007/s10147-021-01881-4. PMID: 34185173
- Bussey HJR, Morson BC: Familial Polyposis Coli. In: Lipkin M, Good RA (eds): *Gastrointestinal Tract Cancer*. Sloan-Kettering Institute Cancer Series. Springer, Boston, MA, 1978
- Iwama T, Tamura K, Morita T, Hirai T, Hasegawa H, Koizumi K, Shirouzu K, Sugihara K, Yamamura T, Muto T, Utsunomiya J; Japanese Society for Cancer of the Colon and Rectum. A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. *Int J Clin Oncol*. 2004 Aug;9(4):308-16. doi: 10.1007/s10147-004-0414-4. PMID: 15375708
- Nielsen M, Hes FJ, Nagengast FM et al (2007) Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. *Clin Genet* 71:427–433
- Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, Kuwada SK, Neklason DW, Disario JA, Lyon E, Hughes JP, Chey WY, White RL. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. *Gastroenterology*. 2004 Aug;127(2):444-51. doi: 10.1053/j.gastro.2004.05.003. PMID: 15300576
- Kobayashi H, Ishida H, Ueno H, Hinoi T, Inoue Y, Ishida F, Kanemitsu Y, Konishi T, Yamaguchi T, Tomita N, Matsubara N, Watanabe T, Sugihara K. Association between the age and the development of colorectal cancer in patients with familial adenomatous polyposis: a multi-institutional study. *Surg Today*. 2017 Apr;47(4):470-475. doi: 10.1007/s00595-016-1398-1. Epub 2016 Aug 9. PMID: 27506752
- Jasperson KW, Patel SG, Ahnen DJ (1993–2020) APC-associated polyposis conditions. 1998 Dec 18 [updated 2017 Feb 2 In: Adam MP, Ardinger HH, Pagon RA, et al., editors. *GeneReviews®* [Internet]. University of Washington, Seattle. Available via [http:// www.ncbi.nlm.nih.gov/books/NBK1245/](http://www.ncbi.nlm.nih.gov/books/NBK1245/)
- Vasen HF, Möslin G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Järvinen H, Mecklin JP, Möller P, Myrhaei T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J. Guidelines for the clinical management of familial adenomatous polyposis (FAP). *Gut*. 2008 May;57(5):704-13. doi: 10.1136/gut.2007.136127. Epub 2008 Jan 14. PMID: 18194984
- Lynch PM, Morris JS, Wen S, Advani SM, Ross W, Chang GJ, Rodriguez-Bigas M, Raju GS, Ricciardiello L, Iwama T, Rossi BM, Pellise M, Stoffel E, Wise PE, Bertario L, Saunders B, Burt R, Belluzzi A, Ahnen D, Matsubara N, Bülow S, Jespersen N, Clark SK, Erdman SH, Markowitz AJ, Bernstein I, De Haas N, Syngal S, Moeslein G. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. *Gastrointest Endosc*. 2016 Jul;84(1):115-125.e4. doi: 10.1016/j.gie.2015.12.029. Epub 2016 Jan 6. PMID: 26769407



10. Septer S, Lawson CE, Anant S, Attard T. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate. *Fam Cancer*. 2016 Jul;15(3):477-85. doi: 10.1007/s10689-016-9905-5.PMID: 27056662
11. Rozen P, Macrae F. Familial adenomatous polyposis: The practical applications of clinical and molecular screening. *Fam Cancer*. 2006;5(3):227-35. doi: 10.1007/s10689-005-5674-2.PMID: 16998668
12. Mori Y, Ishida H, Chika N, Ito T, Amano K, Chikatani K, Takeuchi Y, Kono M, Shichijo S, Chino A, Nagasaki T, Takao A, Takao M, Nakamori S, Sasaki K, Akagi K, Yamaguchi T, Tanakaya K, Naohiro T, Ajioka Y. Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis. *Int J Clin Oncol*. 2023 Dec;28(12):1641-1650. doi: 10.1007/s10147-023-02419-6. Epub 2023 Oct 18.PMID: 37853284
13. Sturt NJ, Gallagher MC, Bassett P, Philp CR, Neale KF, Tomlinson IP, Silver AR, Phillips RK. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. *Gut*. 2004 Dec;53(12):1832-6. doi: 10.1136/gut.2004.042705.PMID: 15542524
14. Crabtree MD, Tomlinson IP, Talbot IC, Phillips RK. Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. *Gut*. 2001 Oct;49(4):540-3. doi: 10.1136/gut.49.4.540.PMID: 11559652
15. Olsen KØ, Juul S, Bülow S, Järvinen HJ, Bakka A, Björk J, Oresland T, Laurberg S. Female fecundity before and after operation for familial adenomatous polyposis. *Br J Surg*. 2003 Feb;90(2):227-31. doi: 10.1002/bjs.4082.PMID: 12555301
16. Rozen P, Samuel Z, Rabau M, Goldman G, Shomrat R, Legum C, Orr-Urtreger A. Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. *Fam Cancer*. 2001;1(2):75-82. doi: 10.1023/a:1013888226756.PMID: 14574001
17. Eccles DM, Lunt PW, Wallis Y, Griffiths M, Sandhu B, McKay S, Morton D, Shea-Simonds J, Macdonald F. An unusually severe phenotype for familial adenomatous polyposis. *Arch Dis Child*. 1997 Nov;77(5):431-5. doi: 10.1136/adc.77.5.431.PMID: 9487968
18. Ishikawa H, Mutoh M, Iwama T, Suzuki S, Abe T, Takeuchi Y, Nakamura T, Ezoe Y, Fujii G, Wakabayashi K, Nakajima T, Sakai T. Endoscopic management of familial adenomatous polyposis in patients refusing colectomy. *Endoscopy*. 2016 Jan;48(1):51-5. doi: 10.1055/s-0034-1392774. Epub 2015 Sep 9. PMID: 26352809
19. Ishikawa H, Yamada M, Sato Y, Tanaka S, Akiko C, Tajika M, Doyama H, Takayama T, Ohda Y, Horimatsu T, Sano Y, Tanakaya K, Ikematsu H, Saida Y, Ishida H, Takeuchi Y, Kashida H, Kiriya S, Hori S, Lee K, Tashiro J, Kobayashi N, Nakajima T, Suzuki S, Mutoh M; J-FAPP Study III Group. Intensive endoscopic resection for downstaging of polyp burden in patients with familial adenomatous polyposis (J-FAPP Study III): A multicenter prospective interventional study. *Endoscopy*. 2023 Apr;55(4):344-352. doi: 10.1055/a-1945-9120. PMID: 36216266
20. Aziz O, Athanasiou T, Fazio VW, Nicholls RJ, Darzi AW, Church J, Phillips RK, Tekkis PP. Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis. *Br J Surg*. 2006 Apr;93(4):407-17. doi: 10.1002/bjs.5276.PMID: 16511903
21. Ten YV, Tillyashakhov M, Islamov H, Ziyaev Y. The risk of malignization incidence in patients with polyps and polyposis of the colon and rectum. *Ann Oncol*. 2019;30:ix37.
22. Ardoino I, Signoroni S, Malvicini E, Ricci MT, Biganzoli EM, Bertario L, Occhionorelli S, Vitellaro M. Long-term survival between total colectomy versus proctocolectomy in patients with FAP: a registry-based, observational cohort study. *Tumori*. 2020 Apr; 106(2): 139-148. doi: 10.1177/0300891619868019.
23. Poylin VY, Shaffer VO, Felder SI, Goldstein LE, Goldberg JE, Kalady MF, Lightner AL, Feingold DL, Paquette IM; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Adenomatous Polyposis Syndromes. *Dis Colon Rectum*. 2024 Feb 1;67(2):213-227. doi: 10.1097/DCR.0000000000003072. PMID: 37682806
24. Church J, Burke C, McGannon E, Pastean O, Clark B. Predicting polyposis severity by proctoscopy: how reliable is it? *Dis Colon Rectum*. 2001;44:1249-1254.

25. Nieuwenhuis MH, Bülow S, Björk J, Järvinen HJ, Bülow C, Bisgaard ML, Vasen HF. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. *Dis Colon Rectum*. 2009 Jul;52(7):1259-63. doi: 10.1007/DCR.0b013e3181a0d33b. PMID: 19571702
26. Aelvoet AS, Struik D, Bastiaansen BAJ, Bemelman WA, Hompes R, Bossuyt PMM, Dekker E. Colectomy and desmoid tumours in familial adenomatous polyposis: a systematic review and meta-analysis. *Fam Cancer*. 2022 Oct;21(4):429-439. doi: 10.1007/s10689-022-00288-y. PMID: 35022961
27. von Roon AC, Will OC, Man RF, et al. Mucosectomy with handsewn anastomosis reduces the risk of adenoma formation in the anorectal segment after restorative proctocolectomy for familial adenomatous polyposis. *Ann Surg*. 2011;253:314–317.
28. Tatsuta K, Sakata M, Iwaizumi M, Okamoto K, Yoshii S, Mori M, Asaba Y, Harada T, Shimizu M, Kurachi K, Takeuchi H. Long-term prognosis after stapled and hand-sewn ileal pouch-anal anastomoses for familial adenomatous polyposis: a multicenter retrospective study. *Int J Colorectal Dis*. 2024 Mar 2;39(1):32. doi: 10.1007/s00384-024-04608-9. PMID: 38431759
29. Rottoli M, Tanzanu M, Lanci AL, Gentilini L, Boschi L, Poggioli G. Mesenteric lengthening during pouch surgery: technique and outcomes in a tertiary centre. *Updates Surg*. 2021 Apr;73(2):581-586. DOI: 10.1007/s13304-021-00984-x. PMID: 33492620
30. Baig MK, Weiss EG, Nogueras JJ, Wexner SD. Lengthening of small bowel mesentery: stepladder incision technique. *Am J Surg*. 2006 May;191(5):715-7. doi: 10.1016/j.amjsurg.2005.08.032. PMID: 16647367
31. Smith L, Friend WG, Medwell SJ. The superior mesenteric artery. The critical factor in the pouch pull-through procedure. *Dis Colon Rectum*. 1984 Nov;27(11):741-4. DOI: 10.1007/BF02554606. PMID: 6499610
32. Martel P, Majery N, Savigny B, Sezeur A, Gallot D, Malafosse M. Mesenteric lengthening in ileoanal pouch anastomosis for ulcerative colitis: Is high division of the superior mesenteric pedicle a safe procedure? *Dis Colon Rectum*. 1998 Jul;41(7):862-6; discussion 866-7. DOI: 10.1007/BF02235366. PMID: 9678371
33. Cherqui D, Valleur P, Perniceni T, Hautefeuille P. Inferior reach of ileal reservoir in ileoanal anastomosis. Experimental anatomic and angiographic study. *Dis Colon Rectum*. 1987 May;30(5):365-71. DOI: 10.1007/BF02555456. PMID: 3568927
34. Martel P, Blanc P, Bothereau H, Malafosse M, Gallot D. Comparative anatomical study of division of the ileocolic pedicle or the superior mesenteric pedicle for mesenteric lengthening. *Br J Surg*. 2002 Jun;89(6):775-8. DOI: 10.1046/j.1365-2168.2002.02101.x. PMID: 12027990
35. Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T, Hinoi T, Kanemitsu Y, Inoue Y, Tomita N, Matsubara N, Komori K, Ozawa H, Nagasaka T, Hasegawa H, Koyama M, Akagi Y, Yatsuoka T, Kumamoto K, Kurachi K, Tanakaya K, Yoshimatsu K, Watanabe T, Sugihara K, Ishida H. Prevalence of laparoscopic surgical treatment and its clinical outcomes in patients with familial adenomatous polyposis in Japan. *Int J Clin Oncol*. 2016 Aug;21(4):713-722. doi: 10.1007/s10147-016-0953-5. PMID: 26820718
36. Konishi T, Ishida H, Ueno H, Kobayashi H, Hinoi T, Inoue Y, Ishida F, Kanemitsu Y, Yamaguchi T, Tomita N, Matsubara N, Watanabe T, Sugihara K. Feasibility of laparoscopic total proctocolectomy with ileal pouch-anal anastomosis and total colectomy with ileorectal anastomosis for familial adenomatous polyposis: results of a nationwide multicenter study. *Int J Clin Oncol*. 2016 Oct;21(5):953-961. doi: 10.1007/s10147-016-0977-x. PMID: 27095110
37. Campos FG. Surgical treatment of familial adenomatous polyposis: dilemmas and current recommendations. *World J Gastroenterol*. 2014 Nov 28;20(44):16620-9. doi: 10.3748/wjg.v20.i44.16620. PMID: 25469031
38. Kjaer MD, Laursen SB, Qvist N, Kjeldsen J, Poornoroosy PH. Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis. *World J Surg*. 2014 Sep;38(9):2460-5. doi: 10.1007/s00268-014-2557-4. PMID: 24711157
39. Fajardo AD, Dharmarajan S, George V, Hunt SR, Birnbaum EH, Fleshman JW, Mutch MG. Laparoscopic versus open 2-stage ileal pouch: laparoscopic approach allows for faster restoration of intestinal continuity. *J Am Coll Surg*. 2010 Sep;211(3):377-83. doi: 10.1016/j.jamcollsurg.2010.05.018. PMID: 20800195
40. Heuthorst L, Wasmann KATGM, Reijntjes MA, Hompes R, Buskens CJ, Bemelman WA. Ileal Pouch-anal Anastomosis Complications and Pouch Failure: A systematic review and meta-analysis. *Ann Surg Open*. 2021 Jun 21;2(2):e074. DOI: 10.1097/AS9.0000000000000074. eCollection 2021 Jun. PMID: 37636549

41. Okita Y, Araki T, Kawamura M, Kondo S, Inoue M, Kobayashi M, Toiyama Y, Ohi M, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M. Clinical features and management of afferent limb syndrome after ileal pouch-anal anastomosis for ulcerative colitis. *Surg Today*. 2016 Oct;46(10):1159-65. DOI: 10.1007/s00595-016-1307-7. Epub 2016 Jan 22. PMID: 26801343
42. Kjaer MD, Laursen SB, Qvist N, Kjeldsen J, Poornoroosy PH. Sexual function and body image are similar after laparoscopy-assisted and open ileal pouch-anal anastomosis. *World J Surg*. 2014 Sep;38(9):2460-5. DOI: 10.1007/s00268-014-2557-4. PMID: 24711157
43. Oresland T, Palmblad S, Ellström M, Berndtsson I, Crona N, Hultén L. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. *Int J Colorectal Dis*. 1994 May;9(2):77-81. doi: 10.1007/BF00699417. PMID: 8064194
44. Koskenvuo L, Renkonen-Sinisalo L, Järvinen HJ, Lepistö A. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. *Int J Colorectal Dis*. 2014 Feb;29(2):225-30. doi: 10.1007/s00384-013-1796-4. Epub 2013 Nov 30. PMID: 24292488
45. Campos FG, Perez RO, Imperiale AR, Seid VE, Nahas SC, Cecconello I. Surgical treatment of familial adenomatous polyposis: ileorectal anastomosis or restorative proctectomy? *Arq Gastroenterol*. 2009 Oct-Dec;46(4):294-9. doi: 10.1590/s0004-28032009000400009. PMID: 20232009
46. Sriranganathan D, Kilic Y, Nabil Quraishi M, Segal JP. Prevalence of pouchitis in both ulcerative colitis and familial adenomatous polyposis: a systematic review and meta-analysis. *Colorectal Dis*. 2022;24:27–39.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.